<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255606</url>
  </required_header>
  <id_info>
    <org_study_id>AVENTIS-FIN-1-2003</org_study_id>
    <secondary_id>CDR0000442891</secondary_id>
    <secondary_id>FINNISH-URO-OGS-1-2003</secondary_id>
    <secondary_id>PROSTY-FIN-1-2003</secondary_id>
    <secondary_id>ICORG-06-14-Prosty</secondary_id>
    <secondary_id>EU-20891</secondary_id>
    <nct_id>NCT00255606</nct_id>
  </id_info>
  <brief_title>Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer</brief_title>
  <official_title>A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It&#xD;
      is not yet known which schedule of docetaxel and prednisone is more effective in treating&#xD;
      prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying two different schedules of docetaxel and&#xD;
      prednisone to compare how well they work in treating patients with metastatic prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the time to treatment failure in patients with hormone-refractory metastatic&#xD;
           prostate cancer treated with two different schedules of docetaxel in combination with&#xD;
           prednisone.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the response rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the need for epoetin beta in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the effect of epoetin beta on hemoglobin response rate, transfusion rate, and&#xD;
           quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, multicenter study. Patients are stratified&#xD;
      according to participating center and WHO performance status (0-1 vs 2). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone&#xD;
           once daily on days 1-28. Courses repeat every 28 days in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on&#xD;
           days 1-21. Courses repeat every 21 days in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients who experience anemia (hemoglobin &lt; 11 g/dL) receive epoetin beta subcutaneously&#xD;
      once weekly during chemotherapy.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 6 weeks during study treatment, at completion&#xD;
      of study treatment, and then every 2 months thereafter.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 360 patients (180 per treatment arm) will be accrued for this&#xD;
      study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life every 6 weeks until TTF</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of epoetin beta</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given in 3- or 4- week courses</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given in 3- or 4- week courses</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic disease by imaging or clinical examination&#xD;
&#xD;
          -  Hormone-refractory disease, defined as prostate-specific antigen (PSA) level &gt; 10 µg/L&#xD;
             AND rising between 2 sequential measurements&#xD;
&#xD;
          -  Testosterone within castration levels by orchiectomy or medical castration comprising&#xD;
             luteinizing hormone-releasing hormone (LHRH) analogues&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 11.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 6 times ULN (unless due to the presence of extensive bone&#xD;
             disease)&#xD;
&#xD;
          -  No serious liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No ischemic or thromboembolic cardiac disease&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No other serious cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary emboli&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No autoimmune disease, including any of the following:&#xD;
&#xD;
               -  Lupus&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Rheumatoid polyarthritis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active peptic ulcer&#xD;
&#xD;
          -  No unstable diabetes mellitus&#xD;
&#xD;
          -  No contraindication to corticosteroids&#xD;
&#xD;
          -  No other malignant disease within the past 5 years except basalioma&#xD;
&#xD;
          -  No functional iron deficiency (i.e., transferrin saturation &lt; 20%) that cannot be&#xD;
             treated with iron supplementation&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 2 months since prior recombinant human epoetin alfa or any other&#xD;
             erythropoiesis-stimulating drug&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior estramustine&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior antiandrogen treatment&#xD;
&#xD;
          -  Concurrent chemical castration with LHRH allowed provided patient has begun treatment&#xD;
             prior to study entry&#xD;
&#xD;
               -  No initiation of chemical castration therapy during study treatment&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No prior radioisotope therapy&#xD;
&#xD;
          -  Concurrent local palliative radiotherapy for pain allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other prior cytostatic treatment&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed provided patient has begun treatment prior to study&#xD;
             entry&#xD;
&#xD;
               -  No initiation of bisphosphonates during study treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirkko Kellokumpu-Lehtinen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kainuu Central Hospital</name>
      <address>
        <city>Kajaani</city>
        <zip>87140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keski-Pohjanmaa Central Hospital</name>
      <address>
        <city>Kokkola</city>
        <zip>67200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymenlaakso Central Hospital</name>
      <address>
        <city>Kotka</city>
        <zip>48210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>FIN-90014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Satakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bons Secours Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Western Cancer Centre at Mid-Western Regional Hospital</name>
      <address>
        <city>Limerick</city>
        <zip>0009</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karlstad Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <zip>65185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Ireland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

